VIENNA, Austria, May 4 /PRNewswire/ -- - Sanochemia USA: operating activities commence US approval for HIV 2 confirmation test expected soon
Sanochemia Pharmazeutika AG, listed in the Prime Segment of the Frankfurt Stock Exchange, announces the April operational start of its US subsidiary Sanochemia Corporation which is based in Westport, Connecticut, a suburb of New York City.
Sanochemia Corporation is headed by its General Manager Ronald “Chip” Stephens who holds a MS in Virology and has extensive experience in the human diagnostics market and in dealings with US regulatory agencies and the US public health system.
Mr Stephens previously was a Division Manager of the Blood Virus Section for Genetic Systems / Sanofi Pasteur, a National Sales Manager for Home Access Health and began his career with Becton Dickinson’s BBL Microbiology division.
According to Mr. Stephens, “In the near-term we expect to secure a significant market share for all Sanochemia products in the US such as diagnostics, APIs, as well as pharmaceutical products,” Sales of Sanochemia’s HIV-1 confirmation test, Fluorognost, have been excellent and show a clear positive trend. Chip also foresees great opportunities for Sanochemia’s range of fine chemicals and specialty chemical contracting business.
HIV 2 Fluorognost test
Sanochemia hopes to see its Fluorognost HIV-2 confirmation assay soon to become an addition to Sanochemia’s product range and to serve as a supplemental HIV-2 test along with the Fluorognost HIV-1 confirmation product. The final marketing authorization is now pending at the CBER division of the US FDA. Demand should be significant given the absence of any other approved HIV-2 confirmation assay on the US market.
Further information about all Sanochemia Corporation products, ordering , etc., can be found on the company’s new US website at http://www.sanochem.com/.
SANOCHEMIA Pharmazeutika AG
CONTACT: Contact: M. Hoch, Tel.: +43-1-319-14-5635, email:m.hoch@sanochemia.at
